Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marcelo F. Benveniste is active.

Publication


Featured researches published by Marcelo F. Benveniste.


British Journal of Radiology | 2012

The reversed halo sign: update and differential diagnosis

Myrna Cobos Barco Godoy; Chitra Viswanathan; Edson Marchiori; M T Truong; Marcelo F. Benveniste; S Rossi; Edith M. Marom

The reversed halo sign is characterised by a central ground-glass opacity surrounded by denser air-space consolidation in the shape of a crescent or a ring. It was first described on high-resolution CT as being specific for cryptogenic organising pneumonia. Since then, the reversed halo sign has been reported in association with a wide range of pulmonary diseases, including invasive pulmonary fungal infections, paracoccidioidomycosis, pneumocystis pneumonia, tuberculosis, community-acquired pneumonia, lymphomatoid granulomatosis, Wegener granulomatosis, lipoid pneumonia and sarcoidosis. It is also seen in pulmonary neoplasms and infarction, and following radiation therapy and radiofrequency ablation of pulmonary malignancies. In this article, we present the spectrum of neoplastic and non-neoplastic diseases that may show the reversed halo sign and offer helpful clues for assisting in the differential diagnosis. By integrating the patients clinical history with the presence of the reversed halo sign and other accompanying radiological findings, the radiologist should be able to narrow the differential diagnosis substantially, and may be able to provide a presumptive final diagnosis, which may obviate the need for biopsy in selected cases, especially in the immunosuppressed population.


Radiographics | 2011

Role of Imaging in the Diagnosis, Staging, and Treatment of Thymoma

Marcelo F. Benveniste; Melissa L. Rosado-de-Christenson; Bradley S. Sabloff; Cesar A. Moran; Stephen G. Swisher; Edith M. Marom

Thymoma is a rare mediastinal neoplasm but is the most common primary neoplasm of the anterior mediastinum. There have been only a few published reports assessing this disease. Furthermore, many of these reports are from a single institution and span several decades, which may lead to potentially misleading conclusions related to diagnosis, staging, and treatment. Computed tomography is the imaging modality of choice for evaluating thymoma and can help distinguish thymoma from other anterior mediastinal abnormalities. Tumor stage and extent of resection are the most important prognostic factors. Tumors that are encapsulated and are amenable to complete resection have a good prognosis, whereas invasive and unresectable tumors have a poor prognosis regardless of their histologic characteristics. Radiologists must be aware of the full spectrum of imaging findings of thymoma, the standard guidelines for diagnostic evaluation, and how imaging findings affect therapeutic decisions.


Journal of Thoracic Oncology | 2013

FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies

Marcelo F. Benveniste; Cesar A. Moran; Osama Mawlawi; Patricia S. Fox; Stephen G. Swisher; Reginald F. Munden; Edith M. Marom

Introduction: Advanced thymoma (stage III and IV) is difficult to detect by computed tomography (CT), yet it is important to distinguish between early (stage I and II) and advanced disease before surgery, as patients with locally advanced tumors require neoadjuvant chemotherapy to enable effective resection. This study assessed whether the amount of fluorodeoxyglucose (FDG) uptake can predict advanced thymoma and whether it can separate thymoma from thymic cancer. Methods: We retrospectively reviewed FDG positron emission tomography (PET)-CT scans of 51 consecutive newly diagnosed patients with thymic epithelial malignancy. PET-CT findings documented focal FDG activity: SUVmax, SUVmean, SUVpeak, and total body volumetric standardized uptake value (SUV) measurements. These were correlated with Masaoka–Koga staging and World Health Organization classification. Wilcoxon ranked sum tests were used to assess association between SUV and pathological stage, cancer type, and classification. Results: Among the study patients, 37 had thymoma, 12 thymic carcinoma, and 2 thymic carcinoid. Higher focal FDG uptake was seen in patients with type B3 thymoma than in those with type A, AB, B1, or B2 thymoma (p < 0.006). FDG uptake was higher in patients with thymic carcinoma or carcinoid than in patients with thymoma (p < 0.0003), with more variable associations with volumetric SUV measurements. There was no significant association observed between higher focal FDG uptake and advanced-stage disease in thymoma patients (p > 0.09), although greater FDG-avid tumor volume was significantly associated with advanced disease (p < 0.03). Conclusions: Focal FDG uptake cannot predict advanced thymoma but is helpful in distinguishing thymoma from thymic carcinoma, or the more aggressive thymoma, type B3.


Clinical Radiology | 2013

New era of radiotherapy: An update in radiation-induced lung disease

Marcelo F. Benveniste; J. Welsh; Myrna C.B. Godoy; Sonia L. Betancourt; Osama Mawlawi; Reginald F. Munden

Over the last few decades, advances in radiotherapy (RT) technology have improved delivery of radiation therapy dramatically. Advances in treatment planning with the development of image-guided radiotherapy and in techniques such as proton therapy, allows the radiation therapist to direct high doses of radiation to the tumour. These advancements result in improved local regional control while reducing potentially damaging dosage to surrounding normal tissues. It is important for radiologists to be aware of the radiological findings from these advances in order to differentiate expected radiation-induced lung injury (RILD) from recurrence, infection, and other lung diseases. In order to understand these changes and correlate them with imaging, the radiologist should have access to the radiation therapy treatment plans.


Journal of Thoracic Oncology | 2014

A Practical Guide from the International Thymic Malignancy Interest Group (ITMIG) Regarding the Radiographic Assessment of Treatment Response of Thymic Epithelial Tumors Using Modified RECIST Criteria

Marcelo F. Benveniste; Robert J. Korst; Arun Rajan; Frank C. Detterbeck; Edith M. Marom

Measuring tumor response to chemotherapy is important for both clinical decision-making and for multi-institutional studies. Thymoma tends to spread along the pleura: a challenge for accurate tumor measurement. Inaccurate and inconsistent tumor measurements often compromise results from clinical trials that are dependent on identifying response rate and progression-free survival. In this article, we sought to provide a practical guide on how to measure thymoma by the International Thymic Malignancy Interest Group’s recommendations for standard outcome measures. The aim of this article is to clarify this measuring technique, lead to consistency between institutions, and minimize intra- and interobserver variability.


European Journal of Radiology | 2014

Metastases to the breast from extramammary malignancies – PET/CT findings ☆

Ana P. Benveniste; Edith M. Marom; Marcelo F. Benveniste; Osama Mawlawi; Roberto N. Miranda; Wei Yang

Detection of incidental malignant lesions in the breast has a significant clinical impact not only on healthy individuals but also on patients with known malignant disease. This review describes a spectrum of metastatic breast lesions incidentally detected by FDG PET-CT at staging that may be misinterpreted as second primary malignancy. The common non-mammary malignancies that metastasize to the breast include melanoma, hematopoietic malignancies and epithelial cancers. We present the FDG PET-CT features of incidental non-mammary metastases to the breast that may help distinguish primary breast cancer from metastatic disease and aid in the management of patients with a known malignancy.


Magnetic Resonance Imaging Clinics of North America | 2015

State of the Art: MR Imaging of Thymoma

Brett W. Carter; Marcelo F. Benveniste; Mylene T. Truong; Edith M. Marom

Thymoma is the most common primary malignancy of the anterior mediastinum and the most common thymic epithelial neoplasm, but it is a rare tumor that constitutes less than 1% of adult malignancies. Computed tomography (CT) is currently the imaging modality of choice for distinguishing thymoma from other anterior mediastinal masses, characterizing the primary tumor, and staging the disease. However, magnetic resonance imaging is also effective in evaluating and characterizing anterior mediastinal masses and staging thymoma in patients with contraindications to contrast-material-enhanced CT such as contrast allergy and/or renal failure.


Modern Pathology | 2013

Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience

Annikka Weissferdt; Neda Kalhor; Edith M. Marom; Marcelo F. Benveniste; Myrna C.B. Godoy; Arlene M. Correa; Stephen G. Swisher; Cesar A. Moran

The recent proposal for histological subtyping of pulmonary adenocarcinoma by predominant pattern and introduction of the terms adenocarcinoma in situ and minimally invasive adenocarcinoma to replace the term bronchioloalveolar carcinoma by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society has led us to conduct a study of 104 patients with early-stage primary pulmonary adenocarcinoma (T1N0M0), with a view to histological subtype as defined by the new proposal and clinical outcome. None of the clinical parameters of our patient population (type of surgery, age, gender, tumor size, and comorbidities) showed any statistically significant correlation with outcome, except for associated malignancies, which not surprisingly appeared to have a negative impact on survival. In addition, statistical analyses of the histological characteristics to include tumor differentiation and the percentage of a lepidic or bronchioloalveolar component did not show any statistically significant values in terms of survival. Our results failed to show any statistically significant difference of survival between those T1N0M0 adenocarcinomas with a lepidic component and those without, thus questioning the use of terms such as in situ or minimally invasive adenocarcinoma. On the basis of our results, we consider that the outcome for patients with T1N0M0 disease is still best determined by appropriate staging rather than by changes in the pathology nomenclature of adenocarcinoma.


Radiographics | 2017

ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses

Brett W. Carter; Marcelo F. Benveniste; Rachna Madan; Myrna C.B. Godoy; Patricia M. de Groot; Mylene T. Truong; Melissa L. Rosado-de-Christenson; Edith M. Marom

Division of the mediastinum into specific compartments is beneficial for a number of reasons, including generation of a focused differential diagnosis for mediastinal masses identified on imaging examinations, assistance in planning for biopsies and surgical procedures, and facilitation of communication between clinicians in a multidisciplinary setting. Several classification schemes for the mediastinum have been created and used to varying degrees in clinical practice. Most radiology classifications have been based on arbitrary landmarks outlined on the lateral chest radiograph. A new scheme based on cross-sectional imaging, principally multidetector computed tomography (CT), has been developed by the International Thymic Malignancy Interest Group (ITMIG) and accepted as a new standard. This clinical division scheme defines unique prevascular, visceral, and paravertebral compartments based on boundaries delineated by specific anatomic structures at multidetector CT. This new definition plays an important role in identification and characterization of mediastinal abnormalities, which, although uncommon and encompassing a wide variety of entities, can often be diagnosed with confidence based on location and imaging features alone. In other scenarios, a diagnosis may be suggested when radiologic features are combined with specific clinical information. In this article, the authors present the new multidetector CT-based classification of mediastinal compartments introduced by ITMIG and a structured approach to imaging evaluation of mediastinal abnormalities. ©RSNA, 2017.


Radiographics | 2014

Multidetector CT Evaluation of Airway Stents: What the Radiologist Should Know

Myrna C.B. Godoy; David A. Saldaña; Praveen P. Rao; Ioannis Vlahos; David P. Naidich; Marcelo F. Benveniste; Jeremy J. Erasmus; Edith M. Marom; David Ost

Airway stents are increasingly used to treat symptomatic patients with obstructive tracheobronchial diseases who are not amenable to surgical resection or who have poor performance status, precluding them from resection. The most common conditions that are treated with tracheobronchial stents are primary lung cancer and metastatic disease. However, stents have also been used to treat patients with airway stenosis related to a variety of benign conditions, such as tracheobronchomalacia, relapsing polychondritis, postintubation tracheal stenosis, postoperative anastomotic stenosis, and granulomatous diseases. Additionally, airway stents can be used as a barrier method in the management of esophagorespiratory fistulas. Many types of stents are available from different manufacturers. Principally, they are classified as silicone; covered and uncovered metal; or hybrid, which are made of silicone and reinforced by metal rings. The advantages and disadvantages of each type of airway stent are carefully considered when choosing the most appropriate stent for each patient. Multidetector computed tomography plays an important role in determining the cause and assessing the location and extent of airway obstruction. Moreover, it is very accurate in its depiction of complications after airway stent placement.

Collaboration


Dive into the Marcelo F. Benveniste's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brett W. Carter

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Mylene T. Truong

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Myrna C.B. Godoy

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Ana P. Benveniste

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Chitra Viswanathan

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Girish S. Shroff

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Osama Mawlawi

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Patricia M. de Groot

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Sonia L. Betancourt Cuellar

University of Texas MD Anderson Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge